Document Detail


Systemic cyclosporin treatment for high-risk corneal transplantation.
MedLine Citation:
PMID:  22827329     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The success rate for uncomplicated penetrating keratoplasty is very high. However, in high risk patients there is a significantly increased risk for immunologic graft failure and the success rate is relatively poor. Oral cyclosporin A treatment has dramatically decreased the rejection rate in solid organ transplantation. Its oral use in ophthalmology has so far been relatively limited and topical use restricted by poor penetration of the drug into ocular tissues. The favorable results of oral cyclosporin treatment to prevent corneal graft failure in high-risk patients is demonstrated in this study. High-risk corneal transplant patients were selected from the general population scheduled to undergo corneal transplantation. Twenty-two of 277 patients who were operated during a four-year period were regarded as high-risk keratoplasty patients. Systemic cyclosporin A treatment (5mg/kg/day) was given prophylactically to 14 of these patients who were considered to be at high-risk for keratoplasty rejection (CsA group). In addition the patients received a low dose of corticosteroids. Eight similar patients receiving high dose corticosteroids served as a control group (control group). In the CsA group graft survival was 78.6% compared with 37.5% in the control group at 1.5 years. The grafts of patients receiving CsA had a significantly better survival rate (p.o5) than those in control at one and 1.5 years. On the follow-up to four years graft survival in patients treated with CsA was, however, decreasing to 35.7%. The low graft survival in both high-risk groups is in great contrast to graft survival in all patients operated during the same period (93.1%). Systemic cyclosporin treatment when received at the time of the operation is effective in reducing failure from irreversible rejection in high-risk keratoplasty, but for maximal effect, a six-month period of treatment is too short. Subjective side effects were frequent but still acceptable. Blood tests did not reveal any pathological hepatic or renal laboratory values caused by system CsA administration. Careful and frequent follow-ups of the patients are however needed.
Authors:
R J Uusitalo; K Mahlberg; K Krootila; P Ruusuvaara
Related Documents :
14605319 - Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-ana...
17658089 - Carotid angioplasty and stenting is a safe and durable procedure in a community hospital.
19713319 - Low-dose intra-arterial urokinase and aggressive mechanical clot disruption for acute i...
20103199 - Stroke-related mortality in coronary surgery is reduced by the off-pump approach.
15079779 - Long-term restenosis rate of eversion endarterectomy on the internal carotid artery.
20870099 - 10-year stroke prevention after successful carotid endarterectomy for asymptomatic sten...
7902819 - The importance of cellular changes in the conjunctiva of patients with uveitic glaucoma...
25448199 - "honey" can prevent epidural fibrosis development after laminectomy: an experimental st...
23717049 - Opioid rotation in patients initiated on oxycodone or morphine: a register study.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Ocular immunology and inflammation     Volume:  4     ISSN:  0927-3948     ISO Abbreviation:  Ocul. Immunol. Inflamm.     Publication Date:  1996  
Date Detail:
Created Date:  2012-07-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9312169     Medline TA:  Ocul Immunol Inflamm     Country:  England    
Other Details:
Languages:  eng     Pagination:  15-24     Citation Subset:  -    
Affiliation:
Department of Ophthalmology, Helsinki University Central Hospital, Helsinki.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Differential expression of HLA-A and B-alleles on uveal melanoma as determined by immuno-histology.
Next Document:  Association of Propionibacterium acnes endophthalmitis with HLA-DQw5.